MedImmune Announces Winners of Third Annual Research Abstract Competition
"One of our primary objectives at MedImmune is to promote and advancehealth and science education, and this competition allows us to do that forresearchers pursuing advanced degrees in the therapeutic areas of respiratorydisease, inflammation and autoimmunity," said Anthony J. Coyle, Ph.D., vicepresident, research and development and head, inflammation and autoimmunityresearch. "It is encouraging to see the high caliber of scientific researchthat went into the submissions we received. The students represented hereembody the future of science leadership, and we at MedImmune are honored toplay a part in their careers by providing some recognition for their hardwork."
The competition was open to graduate students and postdoctoral fellows inthe United States and around the world. The team of MedImmune judges evaluatedthe abstracts according to the following criteria: Ethics, suitability ofmethods to aims, conclusions confirmed by objective results, scientific value,potential clinical value, originality of work and overall presentation.
The following three winners were selected based on scientific merit,presentation content and delivery:
First Place: University of North Carolina at Chapel Hill PostdoctoralStudent Irving Allen. The title of his abstract is, "The NLRP3 Inflammasome isEssential for the Regulation of Innate Responses to Influenza A VirusInfection."
Second Place: Harvard University Postdoctoral Student Anneli Jaeger. Thetitle of her abstract is, "Tracking of TH17 Cells & New Populations ofIL-17-Expressing Cells with IL-23 Receptor (IL-23R) GFP Reporter Mice."
Third Place: National Institutes of Health National Cancer InstitutePostdoctoral Student Karen Muindi. The title of her abstract is, "CellularLipids & Immunity: Characterization of Glycolipids Binding the AntigenPresenting Molecule CD1."
"I would like to thank everyone at MedImmune for sponsoring thiscompetition," said Irving Allen, first place winner and a student at theUniversity of North Carolina at Chapel Hill. "It has been a great experiencefor me and I am hopeful that this research will ultimately yield therapies totreat a variety of human diseases."
MedImmune is a leading innovation-focused biotechnology company whosemission is to provide better medicines to patients, new medical options forphysicians and rewarding careers to employees. Dedicated to advancing scienceand medicine to help people live better lives, the company is focused oninfection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. Headquartered in Gaithersburg,Maryland, MedImmune has approximately 3,000 employees worldwide and is thewholly owned biologics business for AstraZeneca plc (LSE: AZN.L, NYSE: AZN).For more information, visit MedImmune's website at www.medimmune.com.
You May Also Like